Methylprednisolone Withdrawn Phase 2 Trials for Disseminated Sclerosis Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01710228Alternative Treatment Paradigm for Natalizumab Trial